| Description | DHFR-IN-9 (compound 8A), a dihydrofolate reductase (DHFR) inhibitor, impedes purine and thymidylate biosynthesis, pivotal in cell proliferation and growth. It demonstrates potency against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 with an IC50 of 0.25 μg/mL and exhibits anti-infective properties in mouse systemic and thigh infection models at doses of 2.5 mg/kg and 5 mg/kg administered intraperitoneally (ip). Furthermore, DHFR-IN-9 shows greater anticancer efficacy in a mouse breast cancer model compared to paclitaxel (Y-B0015), at a regimented dosage of 2.5 mg/kg ip every three days [1]. |
| molecular weight | 360.44 |
| Molecular formula | C19H16N6S |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |